Mohanty Srujana, Mahapatra Ashoka
Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, 751019, Odisha, India.
Ann Med Surg (Lond). 2021 Jan 20;62:228-230. doi: 10.1016/j.amsu.2021.01.010. eCollection 2021 Feb.
Tigecycline, a new agent against multidrug-resistant (MDR) bacteria, is especially licensed for use in complicated skin and soft tissue and intra-abdominal infections. We aimed to study the recent activity of tigecycline against MDR skin and soft tissue isolates.
Consecutive isolates (56 , 48 ) were subjected to tigecycline susceptibility testing by Ezy MIC test and interpreted as per European Committee on Antimicrobial Susceptibility Testing.
The minimum inhibitory concentrations (MICs) of tigecycline ranged from 0.016 to 48 μg/mL, with MIC 0.19 μg/mL and MIC 1.0 μg/mL respectively. Seven (6.7%) isolates were resistant to tigecycline, all .
Tigecycline remains a viable therapeutic option against MDR isolates, with excellent activity against and promising activity against . However, the limited availability of alternate therapeutic armamentarium necessitates its use with extreme judiciousness along with continuous monitoring for the emergence and spread of resistance.
替加环素是一种针对多重耐药（MDR）细菌的新型药物，特别获批用于治疗复杂皮肤及软组织感染和腹腔内感染。我们旨在研究替加环素近期对MDR皮肤和软组织分离株的活性。
采用Ezy MIC试验对连续分离株（56株、48株）进行替加环素敏感性测试，并按照欧洲抗菌药物敏感性试验委员会的标准进行解读。
替加环素的最低抑菌浓度（MIC）范围为0.016至48μg/mL，MIC50为0.19μg/mL，MIC90为1.0μg/mL。七株（6.7%）分离株对替加环素耐药，均为[此处原文缺失相关内容]。
替加环素仍然是针对MDR分离株的一种可行治疗选择，对[此处原文缺失相关内容]具有优异活性，对[此处原文缺失相关内容]具有良好活性。然而，由于替代治疗手段有限，必须极其谨慎地使用，并持续监测耐药性的出现和传播。
